These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 23621902

  • 1. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
    Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, Elbasha EH.
    BMC Infect Dis; 2013 Apr 27; 13():190. PubMed ID: 23621902
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
    Elbasha EH, Chhatwal J, Ferrante SA, El Khoury AC, Laires PA.
    Appl Health Econ Health Policy; 2013 Feb 27; 11(1):65-78. PubMed ID: 23355388
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.
    Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, Esteban-Mur R, Elbasha EH.
    Value Health; 2013 Feb 27; 16(6):973-86. PubMed ID: 24041347
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
    Blázquez-Pérez A, San Miguel R, Mar J.
    Pharmacoeconomics; 2013 Oct 27; 31(10):919-31. PubMed ID: 24000086
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
    Dan YY, Ferrante SA, Elbasha EH, Hsu TY.
    Antivir Ther; 2015 Oct 27; 20(2):209-16. PubMed ID: 25105844
    [Abstract] [Full Text] [Related]

  • 6. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
    Athanasakis K, Ferrante SA, Kyriopoulos II, Petrakis I, Hill M, Retsa MP, Kyriopoulos J.
    Clin Ther; 2015 Jul 01; 37(7):1529-40. PubMed ID: 26031617
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
    Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G.
    J Med Econ; 2014 Jan 01; 17(1):77-87. PubMed ID: 24032626
    [Abstract] [Full Text] [Related]

  • 8. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.
    Clin Gastroenterol Hepatol; 2013 Nov 01; 11(11):1503-10. PubMed ID: 23707354
    [Abstract] [Full Text] [Related]

  • 9. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
    Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, Bruno R, Gasbarrini A, Bruno S, Craxì A, Cammà C, WEF study group.
    Dig Liver Dis; 2014 Oct 01; 46(10):936-42. PubMed ID: 25066806
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
    Cammà C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, Capursi V, Gasbarrini A, Alberti A, Craxì A, WEF Study Group.
    J Hepatol; 2013 Oct 01; 59(4):658-66. PubMed ID: 23707373
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
    Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G.
    J Med Econ; 2014 Jan 01; 17(1):65-76. PubMed ID: 24160335
    [Abstract] [Full Text] [Related]

  • 12. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D, Jones J, Baxter L, Shepherd J.
    Health Technol Assess; 2011 Apr 01; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
    Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK, SPRINT-1 investigators.
    Lancet; 2010 Aug 28; 376(9742):705-16. PubMed ID: 20692693
    [Abstract] [Full Text] [Related]

  • 14. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
    Manns MP, McCone J, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM.
    Liver Int; 2014 May 28; 34(5):707-19. PubMed ID: 24118703
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
    Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, Poordad F, Bacon B, Gottesdiener K, Pedicone LD, Albrecht JK, Brass CA, Thompson S, Burroughs MH.
    J Hepatol; 2013 Mar 28; 58(3):479-87. PubMed ID: 23183529
    [Abstract] [Full Text] [Related]

  • 16. Boceprevir for untreated chronic HCV genotype 1 infection.
    Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators.
    N Engl J Med; 2011 Mar 31; 364(13):1195-206. PubMed ID: 21449783
    [Abstract] [Full Text] [Related]

  • 17. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.
    Westerhout K, Treur M, Mehnert A, Pascoe K, Ladha I, Belsey J.
    J Med Econ; 2015 Mar 31; 18(10):838-49. PubMed ID: 25903830
    [Abstract] [Full Text] [Related]

  • 18. Boceprevir for previously treated chronic HCV genotype 1 infection.
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, HCV RESPOND-2 Investigators.
    N Engl J Med; 2011 Mar 31; 364(13):1207-17. PubMed ID: 21449784
    [Abstract] [Full Text] [Related]

  • 19. Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands.
    Vellopoulou A, van Agthoven M, van der Kolk A, de Knegt RJ, Berdeaux G, Cure S, Bianic F, Lamotte M.
    Appl Health Econ Health Policy; 2014 Dec 31; 12(6):647-59. PubMed ID: 25103219
    [Abstract] [Full Text] [Related]

  • 20. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.
    Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, McHutchison JG, Wong JB.
    Pharmacoeconomics; 2009 Dec 31; 27(4):341-54. PubMed ID: 19485429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.